NR AFBJ
AU Hamilton,J.A.; Whitty,G.; White,A.R.; Jobling,M.F.; Thompson,A.; Barrow,C.J.; Cappai,R.; Beyreuther,K.; Masters,C.L.
TI Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF)
QU Brain Research 2002 Jun 14; 940(1-2): 49-54
PT journal article
AB Microglial cells, macrophage-lineage cells in the brain, are increased in amyloid-containing plaques in Alzheimer's disease (AD) and in the lesions of prion diseases. Recent studies suggest that microglia have a central role in turnover of amyloid in these diseases. We report here that synthetic amyloid beta (Abeta) 1-42 and prion protein (PrP) 106-126 peptides promote macrophage survival; they also induce macrophage DNA synthesis, particularly in the presence of sub-optimal concentrations of the growth factor, macrophage-colony stimulating factor (M-CSF or CSF-1). These responses are proposed to provide a means to increase brain microglia/macrophage numbers thereby enhancing subsequent inflammatory/immune responses. These fibrillogenic peptides join the list of aggregates having these effects on macrophages, indicating the generality of this type of response.
MH Amyloid beta-Protein/*pharmacology; Animal; Cell Division/drug effects; Cell Survival/drug effects; Cells, Cultured; DNA/*biosynthesis; Dose-Response Relationship, Drug; Female; Macrophage Colony-Stimulating Factor/*pharmacology; Macrophages/cytology/*drug effects/metabolism; Male; Mice; Peptide Fragments/*pharmacology; Prions/*pharmacology; Time Factors
AD John A. Hamilton (jahami@unimelb.edu.au), Genevieve Whitty, Arthritis and Inflammation Research Centre, The University of Melbourne, Department of Medicine, The Royal Melbourne Hospital, Clinical Sciences Building, Royal Parade, Victoria 3050, Parkville, Australia; Anthony R. White, Michael F. Jobling, Roberto Cappai, Colin L. Masters, Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia; Anthony R. White, Michael F. Jobling, Roberto Cappai, Colin L. Masters, The Mental Health Research Institute, Parkville, Victoria 3052, Australia; Andrew Thompson, Colin J. Barrow, School of Chemistry, The University of Melbourne, Melbourne, Victoria 3010, Australia; Konrad Beyreuther, Centre for Molecular Biology, The University of Heidelberg, IM Neuenheimer Feld 282, 69120 Heidelberg, Germany
SP englisch
PO Niederlande